Clinical Trials for PIK3CA Mutation

Find clinical trials for pik3ca mutation. Discover research opportunities and treatment options in your area.

3 Active Trials Found

Showing 3 trials on this page

Page 1 of 1

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

NCT ID: NCT06789913

This clinical trial is studying a new medication called RLY-2608, which is designed to help people with a condition called PIK3CA-Related Overgrowth Spectrum (PROS) and other related malformations ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Cincinnati, Ohio, United States, St. Louis, Missouri, United States +2 more

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT ID: NCT06982521

This clinical trial is studying two different treatment combinations for patients with a specific type of breast cancer called HR+/HER2- that has a PIK3CA mutation. The researchers want to see how ...

Not yet recruiting

Phase: PHASE3 Type: interventional

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

NCT ID: NCT05216432

This clinical trial is testing a new drug called RLY-2608, which is designed to target a specific genetic mutation (PIK3CA) found in some solid tumors, including certain types of breast cancer. The...

Recruiting

Phase: PHASE1 Type: interventional Locations: Ann Arbor, Michigan, United States, Boston, Massachusetts, United States +36 more

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions